This company has been acquired
La Jolla Pharmaceutical Management
Management criteria checks 3/4
La Jolla Pharmaceutical's CEO is Larry Edwards, appointed in Jul 2020, has a tenure of 2.08 years. total yearly compensation is $2.39M, comprised of 23% salary and 77% bonuses, including company stock and options. directly owns 0.048% of the company’s shares, worth $74.45K. The average tenure of the management team and the board of directors is 2.1 years and 7.7 years respectively.
Key information
Larry Edwards
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 23.02% |
| CEO tenure | 2.1yrs |
| CEO ownership | 0.05% |
| Management average tenure | 2.1yrs |
| Board average tenure | 7.7yrs |
Recent management updates
Recent updates
Innoviva to acquire La Jolla Pharma for $149M including debt
Jul 11We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative
Nov 11
Our Take On La Jolla Pharmaceutical Company
Jul 02La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares
Mar 11Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)
Feb 11Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%
Jan 16Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?
Jan 05Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?
Dec 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | US$4m |
| Mar 31 2022 | n/a | n/a | US$5m |
| Dec 31 2021 | US$2m | US$550k | US$20m |
| Sep 30 2021 | n/a | n/a | US$12m |
| Jun 30 2021 | n/a | n/a | US$3m |
| Mar 31 2021 | n/a | n/a | -US$16m |
| Dec 31 2020 | US$3m | US$208k | -US$39m |
Compensation vs Market: Larry's total compensation ($USD2.39M) is above average for companies of similar size in the US market ($USD1.53M).
Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.
CEO
Larry Edwards (50 yo)
Mr. Larry G. Edwards has been President and Chief Executive Officer at La Jolla Pharmaceutical Company since July 2020. Mr. Edwards serves as Director at La Jolla Pharmaceutical Company since October 29, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$2.39m | 0.048% $ 74.5k | |
| CFO & Secretary | 2.2yrs | US$504.10k | 0.041% $ 63.4k | |
| Vice President of Operations | 1.8yrs | no data | no data | |
| Senior Director of Investor Relations & Human Resources | no data | no data | no data | |
| Senior Vice President of Pharmaceutical Operations | 3.5yrs | no data | no data | |
| Consultant | 7.1yrs | US$707.29k | no data | |
| Chief Development Officer | 2.7yrs | no data | no data | |
| Senior Vice President of Medical Affairs | 1.9yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: LJPC's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$2.39m | 0.048% $ 74.5k | |
| Chairman of the Board | 8yrs | US$105.86k | 0.45% $ 696.6k | |
| Independent Director | 2.8yrs | US$165.86k | 0.40% $ 622.0k | |
| Member of Scientific Advisory Board | 8.5yrs | no data | no data | |
| Independent Director | 8.8yrs | US$165.86k | 0.0020% $ 3.1k | |
| Member of Scientific Advisory Board | 8.5yrs | no data | no data | |
| Independent Director | 8.8yrs | US$180.86k | 0.048% $ 74.6k | |
| Independent Director | 8.1yrs | US$165.86k | 0% $ 0 | |
| Member of Advisory Board | 7.3yrs | no data | no data | |
| Member of Advisory Board | 7.3yrs | no data | no data | |
| Member of Advisory Board | 7.3yrs | no data | no data | |
| Member of Advisory Board | 7.3yrs | no data | no data |
Experienced Board: LJPC's board of directors are considered experienced (7.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/22 23:33 |
| End of Day Share Price | 2022/08/19 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
La Jolla Pharmaceutical Company is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Reni Benjamin | H.C. Wainwright & Co. |
| Eun Kyung Yang | Jefferies LLC |